201 related articles for article (PubMed ID: 31346950)
1. Geographical Disparities of Outcomes of Hepatocellular Carcinoma in France: The Heavier Burden of Alcohol Compared to Hepatitis C.
Costentin CE; Sogni P; Falissard B; Barbare JC; Bendersky N; Farges O; Goutte N
Dig Dis Sci; 2020 Jan; 65(1):301-311. PubMed ID: 31346950
[TBL] [Abstract][Full Text] [Related]
2. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a Western country.
Goutté N; Sogni P; Bendersky N; Barbare JC; Falissard B; Farges O
J Hepatol; 2017 Mar; 66(3):537-544. PubMed ID: 27773614
[TBL] [Abstract][Full Text] [Related]
3. Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.
Lewin M; Gelu-Simeon M; Ostos M; Boufassa F; Sobesky R; Teicher E; Meyer L; Fontaine H; Salmon-Céron D; Samuel D; Seror O; Trinchet JC; Duclos-Vallée JC
Radiology; 2015 Nov; 277(2):443-53. PubMed ID: 25961631
[TBL] [Abstract][Full Text] [Related]
4. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of Nonalcoholic Steatohepatitis- Versus Viral Hepatitis- and Alcohol-Related Liver Disease-Related Hepatocellular Carcinoma.
Hester CA; Rich NE; Singal AG; Yopp AC
J Natl Compr Canc Netw; 2019 Apr; 17(4):322-329. PubMed ID: 30959469
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.
Fenoglio L; Serraino C; Castagna E; Cardellicchio A; Pomero F; Grosso M; Senore C
World J Gastroenterol; 2013 Jun; 19(21):3207-16. PubMed ID: 23745022
[TBL] [Abstract][Full Text] [Related]
8. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
9. Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome.
Bucci L; Garuti F; Camelli V; Lenzi B; Farinati F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Maida M; Felder M; Morisco F; Gasbarrini A; Gemini S; Foschi FG; Missale G; Masotto A; Affronti A; Bernardi M; Trevisani F; ;
Aliment Pharmacol Ther; 2016 Feb; 43(3):385-99. PubMed ID: 26662476
[TBL] [Abstract][Full Text] [Related]
10. Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.
Adhoute X; Pénaranda G; Raoul JL; Edeline J; Blanc JF; Pol B; Campanile M; Perrier H; Bayle O; Monnet O; Beaurain P; Muller C; Castellani P; Le Treut YP; Bronowicki JP; Bourlière M
World J Gastroenterol; 2017 Apr; 23(14):2545-2555. PubMed ID: 28465639
[TBL] [Abstract][Full Text] [Related]
11. Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
Kim NG; Nguyen PP; Dang H; Kumari R; Garcia G; Esquivel CO; Nguyen MH
Cancer; 2018 Jun; 124(12):2588-2598. PubMed ID: 29624631
[TBL] [Abstract][Full Text] [Related]
12. Factors that affect risk for hepatocellular carcinoma and effects of surveillance.
Yang JD; Harmsen WS; Slettedahl SW; Chaiteerakij R; Enders FT; Therneau TM; Orsini L; Kim WR; Roberts LR
Clin Gastroenterol Hepatol; 2011 Jul; 9(7):617-23.e1. PubMed ID: 21459158
[TBL] [Abstract][Full Text] [Related]
13. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area.
Huang YC; Huang CF; Chang KC; Hung SF; Wang JH; Hung CH; Chen CH; Tseng PL; Kee KM; Yen YH; Tsai PS; Tsai CC; Lu SN
J Gastroenterol Hepatol; 2011 Jan; 26(1):129-34. PubMed ID: 21175806
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort.
Sinn DH; Gwak GY; Cho J; Paik SW; Yoo BC
PLoS One; 2014; 9(11):e112184. PubMed ID: 25372403
[TBL] [Abstract][Full Text] [Related]
15. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
16. Does persistent anti-HBc positivity influence the prognosis of HBsAg-negative hepatocellular carcinoma? comparative outcomes of anti-Hbc positive versus anti-Hbc negative non-B non-C HCC.
Law JH; Tan JKH; Wong KYM; Ng WQ; Tan PS; Bonney GK; Iyer SG; Krishnakumar M; Kow WCA
HPB (Oxford); 2019 Feb; 21(2):242-248. PubMed ID: 30087053
[TBL] [Abstract][Full Text] [Related]
17. [Hepatocellular carcinoma in Germany. Epidemiology, etiology, clinical aspects and prognosis in 100 consecutive patients of a university clinic].
Petry W; Heintges T; Hensel F; Erhardt A; Wenning M; Niederau C; Häussinger D
Z Gastroenterol; 1997 Dec; 35(12):1059-67. PubMed ID: 9487638
[TBL] [Abstract][Full Text] [Related]
18. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular Carcinoma in a Tertiary Referral Hospital in Indonesia: Lack of Improvement of One-Year Survival Rates between 1998-1999 and 2013-2014.
Loho IM; Hasan I; Lesmana CR; Dewiasty E; Gani RA
Asian Pac J Cancer Prev; 2016; 17(4):2165-70. PubMed ID: 27221913
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of survival in HIV/HCV co-infected patients with hepatocellular carcinoma: The CARCINOVIC Cohort.
Gelu-Simeon M; Lewin M; Ostos M; Bayan T; Beso Delgado M; Teicher E; Layese R; Roudot-Thoraval F; Fontaine H; Sobesky R; Salmon-Céron D; Samuel D; Seror O; Nahon P; Meyer L; Duclos-Vallée JC;
Liver Int; 2019 Jan; 39(1):136-146. PubMed ID: 29947467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
